Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

TTF1 (Transcription Termination Factor 1)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

TTF1 expression + PD-L1 expression	Lung Adenocarcinoma	TTF1 expression + PD-L1 expression	Lung Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
STK11 deletion + TTF1 positive	Lung Non-Squamous Non-Small Cell Cancer	STK11 deletion + TTF1 positive	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
TTF1 expression	Lung Adenocarcinoma	TTF1 expression	Lung Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
TTF1 expression + PD-L1 overexpression	Lung Adenocarcinoma	TTF1 expression + PD-L1 overexpression	Lung Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
EGFR mutation + TTF1 negative	Lung Adenocarcinoma	EGFR mutation + TTF1 negative	Lung Adenocarcinoma	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
TTF1 negative	Lung Non-Squamous Non-Small Cell Cancer	TTF1 negative	Lung Non-Squamous Non-Small Cell Cancer	ABCP Sensitive: C3 – Early Trials ABCP Sensitive : C3	ABCP Sensitive: C3 – Early Trials ABCP Sensitive : C3
TTF1 expression + NAPSA expression + PD-L1 expression + TMB-H	Lung Adenocarcinoma	TTF1 expression + NAPSA expression + PD-L1 expression + TMB-H	Lung Adenocarcinoma	toripalimab-tpzi Sensitive: C4 – Case Studies toripalimab-tpzi Sensitive : C4	toripalimab-tpzi Sensitive: C4 – Case Studies toripalimab-tpzi Sensitive : C4
TTF1 expression + PD-L1 expression	Lung Adenocarcinoma	TTF1 expression + PD-L1 expression	Lung Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4